Antibodies
19 December 2015
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma18 December 2015
GeNeuro Announces the Launch of Phase IIb Proof-of-Concept Study with GNbAC1 in Multiple Sclerosis and Servier Equity Investment18 December 2015
Durvalumab ATLANTIC trial supports clinical activity and AstraZeneca’s overall immuno-oncology strategy17 December 2015
GSK receives positive top-line results from sirukumab phase III programme supporting regulatory filings for rheumatoid arthritis in 201617 December 2015
Ablynx completes enrolment of the first-in-infant phase I/IIa safety study with its anti-RSV nanobody and extends the trial for younger infants14 December 2015
Complix Advances Novel Biospecific Immunotherapeutic CMX-02 – Enters Agreement with Selexis to Access SUREtechnology Platform™10 December 2015
Seattle Genetics Presents Phase 1 Data from Novel Antibody-Drug Conjugate SGN-LIV1A at San Antonio Breast Cancer Symposium10 December 2015
BIOCAD Scores Another Victory in mAb biosimilars With Marketing Authorization for Bevacizumab9 December 2015
Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Atezolizumab in Renal Cell Carcinoma8 December 2015
Alopexx Oncology Presents Encouraging Phase I/II Clinical Data On DI-Leu16-IL2 At The American Society Of Hematology Annual Meeting8 December 2015
Immunomedics Reports Initial Results of a Phase I First-In-Man Study With IMMU-114 in Hematologic Malignancies8 December 2015
XBiotech Announces Positive Results in European Phase III Study for Its Breakthrough Therapy for Colorectal Cancer8 December 2015
Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data Presentations in Patients with Acute Myeloid Leukemia at ASH 20157 December 2015
Amgen Presents Data From Three Trials Evaluating BLINCYTO® (blinatumomab) In Acute Lymphoblastic Leukemia At ASH 20157 December 2015
New Clinical Data on MorphoSys’s Blood Cancer Drug Candidate MOR208 in NHL and CLL Presented at ASH Annual Meeting7 December 2015
MorphoSys Presents Interim Safety, Pharmacokinetic and Efficacy Data for MOR202 in Multiple Myeloma at ASH Meeting6 December 2015
Affimed Presents Additional Data on Combination of AFM13 with Checkpoint Inhibitors at ASHNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports